---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-016666"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:14:03.901529+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma names Aaron Ondrey CFO; expands leadership team for commercial transition

## Summary
- Aaron Ondrey appointed CFO, effective March 25, 2024; previously CFO of Mirati Therapeutics.
- Compensation: base salary $485k, target bonus 45%, equity grant ~$2.5M (half options, half RSUs) with 3-year vesting.
- Other appointments: Kinnari Patel as President/Head of R&D/COO; Jonathan Schwartz as Chief Medical & Gene Therapy Officer; Mark White as GM Commercial; Martin Wilson as GC/Chief Corporate Officer.
- Leadership changes position Rocket for planned commercial stage transition for gene therapies.

## SEC filing metadata
- accession: 0001140361-24-016666
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/0001140361-24-016666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/ef20025500_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-016666
- JSON: https://secwatch.observer/filing/0001140361-24-016666.json
- Plain text: https://secwatch.observer/filing/0001140361-24-016666.txt

## Key facts
- Executive change
  Aaron Ondrey was appointed as Chief Financial Officer at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Financial Officer and Principal Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/0001140361-24-016666-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.